A. Prerenal B. Tubular necrosis C. Interstitial nephritis D. Postrenal obstruction

A. Colloid Fluid Resuscitation B. Diuresis C. Vasoconstricting Agents D. Transplant Evaluation

A. Terlipressin plus albumin should be considered as the first-line therapeutic option for the treatment of HRS AKI B. Noradrenaline plus albumin should be considered as the first-line therapeutic option for the treatment of HRS AKI C. Midodrine and octreotide plus albumin should be considered as the first-line therapeutic option for the treatment of HRS AKI D. Albumin alone should be considered as the first-line therapeutic option for the treatment of HRS AKI

A. Patients in the placebo group with confirmed CHRSR had significantly longer survival times than patients in the placebo group without CHRSR B. Patients in the terlipressin group with confirmed CHRSR had significantly longer survival times than patients in the placebo group without CHRSR C. Patients in the terlipressin group with confirmed CHRSR had significantly longer survival times than patients in the terlipressin group without CHRSR D. Patients in the placebo group with confirmed CHRSR had significantly longer survival times than patients in the terlipressin group without CHRSR

A. Initiate diuretics, beta-blockers, vasodilators, and other medications that decrease blood volume B. Initiate medications, such as nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors and antibiotics to manage underlying comorbidities C. Optimize the dosing and co-administration of vasoconstrictors (norepinephrine, octreotide, midodrine and terlipressin) with albumin D. Assist in liver and or kidney transplant surgery in those patients with HRS at high risk for renal nonrecovery

A. To focus on restricting medication access through the Formulary process B. To focus on drug cost savings C. To focus solely on the endpoints in clinical trials of HRS reversal and in-hospital mortality D. To focus on improving any or all clinical outcomes (reduced length of stay, shortened course of renal replacement therapy, expanding access to organ transplantation) that reflect the value of medication use